Loading cancer entity…
Loading cancer entity…
Clinical trials
227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (55)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05017610 | Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma | withdrawn | Early Phase 1 | 0 | Emory UniversityOTHER | 0 | Dec 2, 2022 | clinicaltrials |
| NCT04854044 | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT03014804 |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma |
| withdrawn |
| Phase 2 |
| 0 |
| Jonsson Comprehensive Cancer CenterOTHER |
| 1 |
| Jul 24, 2020 |
| clinicaltrials |
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | withdrawn | Phase 1 | 0 | Center Trials & TreatmentOTHER | 2 | Jul 19, 2018 | clinicaltrials |
| NCT02194452 | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors | withdrawn | N/A | 0 | Sue O'DorisioOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT02599090 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 6, 2015 | clinicaltrials |
| NCT02055196 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00734864 | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | withdrawn | Phase 1 | 0 | Annick DesjardinsOTHER | 1 | Nov 21, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Dec 2, 2022source: clinicaltrials